Background: The problem of glycemic variability has been widely acknowledged in patients with diabetes with severe insulin deficiency. In a companion article, we proposed a novel metric, the glycemic variability percentage (GVP), for assessing glycemic variability that accounts for both the amplitude and frequency of glycemic fluctuations.
Method: We applied the new metric, the GVP, to a previously reported case of a subject using an earlier generation continuous glucose monitoring (CGM) device, in which successive periods of use were associated with an apparent decrease in glycemic variability. Results were compared with histogram distributions for the rate of change of glucose as well. The GVP was also applied to data from a published study of a bihormonal artificial pancreas system comparing results from open loop and closed loop in adolescents and in adults.
Results: The GVP was able to quantify the changes in glycemic variability during successive periods of CGM use. Application of the GVP to a published study of a bihormonal artificial pancreas found an increase in glycemic variability compared with other accepted metrics which suggested a decrease in glycemic variability.
Conclusion: The GVP may be a clinically useful tool in characterizing the change in glycemic variability in subjects using CGM devices. Compared with metrics, such as the standard deviation, that focus solely on the amplitude of oscillations, the GVP, which measures both frequency and amplitude, may also be a more useful tool in assessing the true level of glycemic variability in artificial pancreas studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/dia.2017.0188 | DOI Listing |
Diabetes Metab Syndr Obes
January 2025
Department of Diabetes, Metabolism and Endocrinology, Toho University Graduate School of Medicine, Tokyo, Japan.
Purpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. This study aimed to investigate the efficacy of combining imeglimin with dipeptidyl peptidase-4 inhibitor (DPP-4i), the most frequently prescribed first-line treatment for patients with type 2 diabetes (T2D) in Japan, to improve glycemic control.
Patients And Methods: Eleven patients with T2D treated with DPP-4i alone (6.
BMC Public Health
January 2025
Department of Optometry, College of Medicine and Health Sciences, Comprehensive Specialized Hospital, University of Gondar, Gondar, Ethiopia.
Baground: Cataract is a major public health concern and the leading cause of blindness and low vision in Ethiopia. However, no studies have been conducted to assess the prevalence of cataract and associated factors among adult diabetic patients in the study area. Therefore, this study aimed to assess the prevalence of cataract and associated factors among adult diabetic patients in Northwest Ethiopia.
View Article and Find Full Text PDFIndian J Crit Care Med
January 2025
Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Background: Glycemic variability (GV) is the third domain of sepsis-induced dysglycemia, after hyperglycemia and hypoglycemia, potentially leading to adverse outcomes. This study analyzed the association of GV with in-hospital mortality and length of stay (LOS) in non-diabetic sepsis patients.
Materials And Methods: In this prospective observational study, non-diabetic sepsis patients were followed till day 14 of hospital stay, and blood glucose levels were assessed by finger-prick method (seven times per day) daily; clinico-laboratory and GV parameters [standard deviation (SD), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE)] were assessed on days 1, 3, 5, 7, 10, and 14 of admission.
Indian J Crit Care Med
January 2025
Department of Pathology, Gandhi Nagar Hospital, Central Coalfields Ltd, Ranchi, Jharkhand, India.
Prakash J, Vaibhaw V, Saran K. Controlling Glycemic Variability in Non-diabetic Sepsis Patients: A Step toward Precision in Critical Care. Indian J Crit Care Med 2025;29(1):6-7.
View Article and Find Full Text PDFDiabetes Res Clin Pract
January 2025
Division of Endocrinology, University of Texas Southwestern, Dallas, TX, USA. Electronic address:
The benefits of using continuous glucose monitoring (CGM) in hospitalized patients with diabetes remain uncertain. Point-of-care (POC) glucose testing is the standard of care in this setting. We compared the effect of adding CGM to POC testing versus POC testing alone on glycemic outcomes in this population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!